文献速递膀胱癌与上尿路尿路上皮癌

患者与医生对非肌层浸润性膀胱癌行经尿道膀胱肿瘤电切术与化学消融治疗的认知比较

Patient and Provider Perception of Transurethral Resection of Bladder Tumor vs Chemoablation for Nonmuscle-invasive Bladder Cancer Treatment.
PubMed 文献 · J Urol · 2022-09-06

本研究采用混合方法,通过膀胱癌倡导网络对352例非肌层浸润性膀胱癌患者进行网络调查,并对40例患者和20例泌尿外科医生进行深度电话访谈。调查显示210例(60%)患者偏好重复经尿道膀胱肿瘤电切术,142例(40%)偏好膀胱内化学消融;偏好电切术者更重视初始治疗有效性(63%),偏好化学消融者更重视复发风险(55%)。访谈中患者强调手术的情感负担及对复发、术语和癌症相关症状咨询的需求,而医生未强调这些。

要点

  • 352例患者中60%偏好重复电切术,40%偏好膀胱内化学消融。
  • 偏好电切术者63%优先考虑初始治疗有效性,偏好化学消融者55%优先考虑复发风险。
  • 患者访谈强调手术情感负担及对复发、术语和症状咨询的需求,医生未强调。

核心结论

  • 患者与泌尿外科医生对重复经尿道膀胱肿瘤电切术的认知存在差异,理解这种认知有助于在新疗法出现时进行共享决策。

研究设计与样本

  • 混合方法研究:通过膀胱癌倡导网络对至少接受过1次经尿道膀胱肿瘤电切术的非肌层浸润性膀胱癌患者进行网络调查,并进行双变量和多变量分析。
  • 对40例患者和20例泌尿外科医生进行60次深度电话访谈,由受过培训的定性专家实施,转录文本导入Dedoose分析。

主要发现

  • 352例调查患者中210例(60%)偏好重复经尿道膀胱肿瘤电切术,142例(40%)偏好膀胱内化学消融。
  • 偏好重复电切术的患者更可能优先考虑初始治疗有效性(63%),偏好化学消融的患者优先考虑复发风险(55%)。
  • 偏好膀胱内化学消融的相关变量包括美国居住(OR=2;95% CI 1.1, 3.8),以及将复发风险优先于有效性作为治疗偏好理由(OR=14.6;95% CI 7.4, 28.5)。
  • 访谈主题因参与者而异,患者但非泌尿外科医生强调手术的情感负担以及对复发、术语和癌症相关体征症状的咨询需求。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this mixed methods study was to investigate patient and provider perceptions of repeat transurethral resection of bladder tumors to improve counseling as new nonsurgical treatment modalities for nonmuscle-invasive bladder cancer emerge. MATERIALS AND METHODS: Quantitative data were collected via a web-based survey through the Bladder Cancer Advocacy Network of patients with nonmuscle-invasive bladder cancer who had undergone at least 1 transurethral resection of bladder tumor. Bivariable and multivariable analyses were performed to evaluate associations of patient demographics and clinical variables with treatment preference. Qualitative data were collected with 60 in-depth telephone interviews with patients (n=40) and urologists (n=20) to understand experiences with bladder cancer and transurethral resection of bladder tumor. Telephone interviews were conducted by trained qualitative experts. Transcripts were imported into Dedoose to facilitate analysis. RESULTS: Survey data of 352 patients showed 210 respondents (60%) preferred repeat transurethral resection of bladder tumor while 142 (40%) preferred intravesical chemoablation. Patients who preferred repeat transurethral resection of bladder tumor were more likely to prioritize initial treatment effectiveness (63%), whereas those who preferred chemoablation prioritized risk of recurrence (55%). Variables associated with a preference for intravesical chemoablation included U.S. residence (OR=2; 95% CI 1.1, 3.8), or if they expressed their reason for treatment preference as priority of recurrence risk over effectiveness (OR=14.6; 95% CI 7.4, 28.5). Predominant interview themes varied across participants, with patients but not urologists emphasizing the emotional toll of the procedure along with the need for improved counseling regarding recurrence, terminology, and cancer-related signs and symptoms. CONCLUSIONS: Differences exist in the way patients and urologists perceive repeat transurethral resection of bladder tumor for bladder cancer. Understanding transurethral resection of bladder tumor perception will aid in shared decision making as novel treatments emerge for nonmuscle-invasive bladder cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Parisse T, Reines K, Basak R, et al. Patient and Provider Perception of Transurethral Resection of Bladder Tumor vs Chemoablation for Nonmuscle-invasive Bladder Cancer Treatment. J Urol. 2022. PMID: 36067365. doi:10.1097/JU.0000000000002941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。